Alexion Pharmaceuticals, Inc.
Leonard Bell, M.D.
Chief Executive Officer
(203) 272-2596

Noonan/Russo
Matt Haines
(Media)
(212) 845-4235

Rx Communications
Patricia Garrison (Scientific Media)
917-322-2567
Rhonda Chiger (Investor)
(917) 322-2569

Alexion Pharmaceuticals Soliris(TM) (Eculizumab) data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to Soliris(TM) (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris(TM) (eculizumab) PNH clinical studies.

    The following abstracts will be presented in oral sessions:

     -- "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in

        Patients with Paroxysmal Nocturnal Hemoglobinuria"

        Dr. Peter Hillmen et al.

        Time: Sunday, December 10th at 5:00pm

        Room 315

     -- "Treatment with the Terminal Complement Inhibitor Eculizumab Improves

        Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III

        TRIUMPH Study Results"

        Dr. Jorg Schubert et al.

        Time: Sunday, December 10th at 5:15pm

        Room 315

    The following abstracts will be presented in poster sessions:

     -- "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab

        in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase

        III Clinical Study"

        Poster # 99-I

        Dr. Neal S. Young et al.

        Time: Saturday, December 9th at 9:00am

        Hall E-1

     -- "Blockade of Intravascular Hemolysis in PNH with the Terminal

        Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis

        Potentially Occurring through C3 Opsonization" 

        Poster #100-I

        Dr. Anita Hill et al.

        Time: Saturday, December 9th at 9:00am

        Hall E-1